Mediford Corporation

Contact us

Contact us
© Mediford Corporation

Analytical Solutions for Novel Modalities

In recent years, drug development has expanded beyond small molecule drugs to include a range of molecule sizes ―from medium-sized to large molecules― such as nucleic acid drugs, antibody drugs and gene therapy products, utilizing a variety of drug discovery technologies.

Mediford Corporation leverages decades of expertise in small molecule drugs, combined with cutting-edge equipment, to provide reliable data across various modalities.

Service Details

Determination of Drug Concentrations

Drug modalities Methods Platforms Manufacturer
- Nucleic acid drugs
- Peptide drugs
<Medium-sized molecules>
 - LC/MS*1 QTRAP 7500 AB SCIEX
Q Exactive Focus Thermo Fisher Scientific
- MSI*2 solariX 2XR Bruker
- Hybridization-assay
- LBA*3
 MESO Quick Plex SQ120 Meso Scale Diagnostics
SMCxPRO Merck
Gyrolab xP workstation Gyros Protein Technologies
VersaMax Molecular Devices
- Antibody drugs
(ADC*4, bispecific antibody, etc.)
 - MSI*2 solariX 2XR Bruker
- LBA*3 MESO Quick Plex SQ120 Meso Scale Diagnostics
SMCxPRO Merck
Gyrolab xP workstation Gyros Protein Technologies
VersaMax Molecular Devices
- Gene therapy
(virus vector, plasmid vector, mRNA, etc.)
 - qPCR*5 LightCycler 480Ⅱ Roche Diagnostics
- Cell-based assay
 VersaMax Molecular Devices
- Cell therapy
- Regenerative medicine
(immune system)
- Cancer Immunotherapy
(CAR-T*6, etc.)
 - qPCR*5 LightCycler 480Ⅱ Roche Diagnostics
- Flow cytometry
 BD FACSCantoⅡ BD Biosciences
BD FACSLyric BD Biosciences
CyTOF XT Standard BioTools
  • *1  LC/MS: Liquid chromatography/ mass spectrometry
  • *2  MSI: Mass spectrometry imaging
  • *3  LBA: Ligand binding assay
  • *4  ADCs: Antibody drug conjugates
  • *5  qPCR: Quantitative polymerase chain reaction
  • *6  CAR-T: Chimeric antigen receptor T-cell therapy

Immunogenicity assessment (Determination of anti-drug antibody)

Drug modalities Methods Platforms Manufacturer
- Nucleic acid drugs
- Peptide drugs
- Antibody drugs
- Gene and cell therapies
- LBA*1
(including cell-based assay for neutralization antibody assay)
 MESO Quick Plex SQ120 Meso Scale Diagnostics
SMCxPRO Merck
Gyrolab xP workstation Gyros Protein Technologies
VersaMax Molecular Devices
- Gene and Cell therapies*2
- Flow cytometry
- Cell-based assay
 BD FACSCantoⅡ BD Biosciences
BD FACSLyric BD Biosciences
CyTOF XT Standard BioTools
  • *1  LBA: Ligand binding assay
  • *2  Used for analysis of anti-drug antibodies on cell surface

Pharmacometrics analysis

Drug modalities Object of evaluation Methods Platforms Manufacturer
- Nucleic acid medicine
- Peptide medicine
- Antibody pharmaceutical
- Gene and Cell therapy
- Spatial distribution
- Gene and protein expression profiling
- GeoMx Digital Spatial Profiler
- nCounter Analysis System
 NanoString Technologies
- Biomarker - LBA*1 SMCxPRO Merck
MESO Quick Plex SQ120 Meso Scale Diagnostics
- Cellular immunity
(vaccine)
 - Flow cytometry BD FACSCantoⅡ BD Biosciences
BD FACSLyric BD Biosciences
CyTOF XT Standard BioTools
- Cell-based assay
 ImmunoSpot Analyzer Cellular Technology Limited
- Intermolecular interaction
 - LBA*1 VersaMax Molecular Devices
Gyrolab xP workstation Gyros Protein Technologies
- Gene mutation
and genotyping
 - Microarray GeneTitan Multi-channel Instrument Thermo Fisher Scientific
- qPCR*2 LightCycler 480Ⅱ Roche Diagnostics
- Sequencing Applied Biosystems 3500xLGenetic Analyzer Thermo Fisher Scientific
- Cell population
- Flow cytometry
 BD FACSCantoⅡ BD Biosciences
BD FACSLyric BD Biosciences
CyTOF XT Standard BioTools
  • *1  LBA: Ligand binding assay
  • *2  qPCR: Quantitative polymerase chain reaction